Doctors in UK need more training on insomnia diagnosis, says Datamonitor, predicting market growth

28 July 2010

More than 3.25 million people in the UK are estimated to meet the diagnostic criteria for insomnia. However, a sizeable proportion of patients do not seek medical advice and doctors aren't suitably prepared to identify and address the problem suggests independent market analyst Datamonitor.

Charlotte Mackey, senior healthcare analyst at Datamonitor, said: 'Key opinion leaders interviewed by Datamonitor expressed a strong belief that despite the high prevalence of insomnia, improvement in recognition, diagnosis and treatment is required. In particular, improved physician training in relation to insomnia is recommended.

'The key issue is that a sizeable proportion of patients do not seek medical advice about sleeping problems, with the majority either ignoring the problem or using self-help methods such as alcohol, natural remedies or over-the-counter (OTC) products'.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical